Compare AVXL & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | CMT |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | 1239 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 201.8M |
| IPO Year | 2013 | 1996 |
| Metric | AVXL | CMT |
|---|---|---|
| Price | $3.15 | $24.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $22.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 958.2K | 19.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $284,290,000.00 |
| Revenue This Year | N/A | $4.58 |
| Revenue Next Year | N/A | $6.04 |
| P/E Ratio | ★ N/A | $342.86 |
| Revenue Growth | N/A | ★ 5.49 |
| 52 Week Low | $2.26 | $16.60 |
| 52 Week High | $11.70 | $28.69 |
| Indicator | AVXL | CMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 47.15 |
| Support Level | $2.93 | $22.82 |
| Resistance Level | $3.07 | $25.38 |
| Average True Range (ATR) | 0.14 | 1.18 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 100.00 | 32.01 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.